About PHARMASEAL
PHARMASEAL is a company based in Nottingham (United Kingdom) founded in 2016 by Daljit Cheema. PHARMASEAL has raised $2.67 million across 3 funding rounds from investors including Mercia and Midlands Engine Investment Fund. The company has 8 employees as of March 31, 2022. PHARMASEAL offers products and services including Engility® CTMS, Engility® eTMF, and Engility® Connect. PHARMASEAL operates in a competitive market with competitors including Advarra, Leucine, Datapharm, Flinn and Health Language, among others.
- Headquarter Nottingham, United Kingdom
- Employees 8 as on 31 Mar, 2022
- Founders Daljit Cheema
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pharmaseal International Limited
- Date of Incorporation 08 Feb, 2016
- Jurisdiction NOTTINGHAM, NOTTINGHAMSHIRE, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2.67 M (USD)
in 3 rounds
-
Latest Funding Round
$673.14 K (USD), Seed
Sep 07, 2020
-
Investors
Mercia
& 1 more
-
Employee Count
8
as on Mar 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of PHARMASEAL
PHARMASEAL offers a comprehensive portfolio of products and services, including Engility® CTMS, Engility® eTMF, and Engility® Connect.
Software for overseeing and executing clinical trials efficiently.
Platform for electronic trial master file handling and storage.
Tool for supply chain collaboration in clinical research processes.
People of PHARMASEAL
Unlock access to complete
Funding Insights of PHARMASEAL
PHARMASEAL has successfully raised a total of $2.67M across 3 strategic funding rounds. The most recent funding activity was a Seed round of $673.14 thousand completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in PHARMASEAL
PHARMASEAL has secured backing from 2 investors, including venture fund and institutional investors. Prominent investors backing the company include Mercia and Midlands Engine Investment Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment funding is provided to support Midlands SMEs growth.
|
Locked | Locked | Locked | |
|
Investment management services are provided by Mercia to various clients.
|
Locked | Locked | Locked |
Investor details for PHARMASEAL
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by PHARMASEAL
Investment portfolio details for PHARMASEAL
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - PHARMASEAL
Detailed financials for PHARMASEAL
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pharmaseal Comparisons
Peer comparison for PHARMASEAL
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of PHARMASEAL
PHARMASEAL operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Advarra, Leucine, Datapharm, Flinn and Health Language, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Global research compliance services including IRB and consulting are provided.
|
|
| Locked | Locked | Locked |
Developer of AI-powered software for pharmaceutical manufacturing, quality, and laboratory
|
|
| Locked | Locked | Locked |
Regulatory compliance software for pharma and healthcare professionals is provided.
|
|
| Locked | Locked | Locked |
Compliance processes are automated for medical device manufacturers using AI.
|
|
| Locked | Locked | Locked |
Enterprise terminology management for medical coding is offered.
|
Detailed competitors of PHARMASEAL
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pharmaseal
Complete news archive for PHARMASEAL
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about PHARMASEAL
PHARMASEAL was founded in 2016 and raised its 1st funding round 2 years after it was founded.
PHARMASEAL is headquartered in Nottingham, United Kingdom.
Daljit Cheema is the current CEO of PHARMASEAL. They have also founded this company.
PHARMASEAL is a funded company, having raised a total of $2.67M across 3 funding rounds to date.
As of Mar 31, 2022, the latest employee count at PHARMASEAL is 8.
PHARMASEAL was founded in 2016 in Nottingham, United Kingdom, as a SaaS-based B2B platform focused on clinical trial governance for biopharmaceutical companies. A cloud-based system is provided to manage and monitor trials in compliance with good clinical practice standards. The product Engility supports study and task management. Modules for patient safety and license-regulatory tools are planned for development. Operations center on regulatory adherence in the biopharma sector.
PHARMASEAL offers Engility® CTMS, Engility® eTMF, and Engility® Connect.
PHARMASEAL has 2 investors. Key investors include Mercia, and Midlands Engine Investment Fund.